Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru
- PMID: 22110689
- PMCID: PMC3217998
- DOI: 10.1371/journal.pone.0027610
Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru
Abstract
Background: Long-term exposure to anti-tuberculosis medication increases risk of adverse drug reactions and toxicity. The objective of this investigation was to determine factors associated with anti-tuberculosis adverse drug reactions in Lima, Peru, with special emphasis on MDR-TB medication, HIV infection, diabetes, age and tobacco use.
Methodology and results: A case-control study was performed using information from Peruvian TB Programme. A case was defined as having reported an anti-TB adverse drug reaction during 2005-2010 with appropriate notification on clinical records. Controls were defined as not having reported a side effect, receiving anti-TB therapy during the same time that the case had appeared. Crude, and age- and sex-adjusted models were calculated using odds ratios (OR) and 95% confidence intervals (95%CI). A multivariable model was created to look for independent factors associated with side effect from anti-TB therapy. A total of 720 patients (144 cases and 576 controls) were analyzed. In our multivariable model, age, especially those over 40 years (OR = 3.93; 95%CI: 1.65-9.35), overweight/obesity (OR = 2.13; 95%CI: 1.17-3.89), anemia (OR = 2.10; IC95%: 1.13-3.92), MDR-TB medication (OR = 11.1; 95%CI: 6.29-19.6), and smoking (OR = 2.00; 95%CI: 1.03-3.87) were independently associated with adverse drug reactions.
Conclusions: Old age, anemia, MDR-TB medication, overweight/obesity status, and smoking history are independent risk factors associated with anti-tuberculosis adverse drug reactions. Patients with these risk factors should be monitored during the anti-TB therapy. A comprehensive clinical history and additional medical exams, including hematocrit and HIV-ELISA, might be useful to identify these patients.
Conflict of interest statement
Similar articles
-
Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors.PLoS One. 2015 Mar 19;10(3):e0119332. doi: 10.1371/journal.pone.0119332. eCollection 2015. PLoS One. 2015. PMID: 25790076 Free PMC article.
-
Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.Trop Med Int Health. 2020 Mar;25(3):346-356. doi: 10.1111/tmi.13350. Epub 2019 Dec 12. Trop Med Int Health. 2020. PMID: 31758837 Free PMC article.
-
Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study.BMC Infect Dis. 2021 Mar 22;21(1):292. doi: 10.1186/s12879-021-05967-2. BMC Infect Dis. 2021. PMID: 33752637 Free PMC article.
-
HIV infection and multidrug-resistant tuberculosis: the perfect storm.J Infect Dis. 2007 Aug 15;196 Suppl 1:S86-107. doi: 10.1086/518665. J Infect Dis. 2007. PMID: 17624830 Review.
-
Treatment of tuberculosis in children.Expert Rev Anti Infect Ther. 2008 Dec;6(6):939-57. doi: 10.1586/14787210.6.6.939. Expert Rev Anti Infect Ther. 2008. PMID: 19053906 Review.
Cited by
-
The first-line antituberculosis drugs, and their fixed-dose combination induced abnormal sperm morphology and histological lesions in the testicular cells of male mice.Front Cell Dev Biol. 2022 Dec 13;10:1023413. doi: 10.3389/fcell.2022.1023413. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36582470 Free PMC article.
-
Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study.BMC Infect Dis. 2019 Mar 27;19(1):286. doi: 10.1186/s12879-019-3919-1. BMC Infect Dis. 2019. PMID: 30917788 Free PMC article.
-
A hospital-based tuberculosis focal point to improve tuberculosis care provision in a very high burden setting.Public Health Action. 2013 Mar 21;3(1):51-5. doi: 10.5588/pha.12.0073. Public Health Action. 2013. PMID: 26392996 Free PMC article.
-
Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda.SAGE Open Med. 2023 May 3;11:20503121231171350. doi: 10.1177/20503121231171350. eCollection 2023. SAGE Open Med. 2023. PMID: 37152841 Free PMC article.
-
The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis.PLoS One. 2020 Jul 21;15(7):e0236109. doi: 10.1371/journal.pone.0236109. eCollection 2020. PLoS One. 2020. PMID: 32692774 Free PMC article.
References
-
- World Health Organization. Global Turberculosis Control 2010: Epidemiology Strategy Financing. World Health Organization; 2010.
-
- Ministerio de Salud. Norma Técnica de Salud para el Control de la Tuberculosis. 2006. Ministerio de Salud. República de Perú.
-
- Ministerio de Salud. Informe de Gestión: Situación de la Tuberculosis en el Perú. 2008. Estrategia Sanitaria Nacional de Prevención y Control de la Tuberculosis. Ministerio de Salud. Lima, Perú.
-
- USAID. Tuberculosis profile: Peru. USAID Press June; 2009. pp. 1–2.
-
- Bernabe-Ortiz A. La pobreza contraataca: Efectos sobre los resultados del TBC-DOTS en el Perú. Rev Med Hered. 2007;18:179–180.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources